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ABSTRACT The allosteric control of aspartate transcar-
bamoylase (ATCase, EC 2.1.3.2) of Escherichia coli involves
feedback inhibition by both CTP and UTP rather than just
CTP alone. It has been known that CTP functions as a
heterotropic inhibitor of catalysis; however, the inhibition by
CTP alone is incomplete (50-70% at various aspartate concen-
trations) and there is only a partial occupancy of the allosteric
binding sites by CTP at saturating concentrations. The logic of
these allosteric characteristics can now be understood in that
UTP is a synergistic inhibitor ofATCase in the presence ofCTP
even though UTP has no independent effect at pH 7.0. When
saturating concentrations of CTP are present, the concentra-
tion of substrate required for half-maximal activity (So.s) of the
native holoenzyme for aspartate increases from 5 to 11 mM.
When CTP and UTP are both present, the aspartate require-
ment increases further (S0.5 = 17 mM). At aspartate concen-
trations <5 mM, the heterotropic inhibition of ATCase is 90-
95% in the presence of both pyrimidine nucleotides. UTP does
enhance the binding ofCTP to the holoenzyme but the number
of tight binding sites does not change (n = 3). The binding of
UTP is stabilized in the presence of CTP although its binding
characteristics are not as strong as those of CTP. The recent
crystallographic studies of Kim et al. [Kim, H.K., Pan, Z.,
Honzatko, R.B., Ke, H.M. & Lipscomb, W.N. (1987) J. Mol.
Biol. 196, 853-875] have described a structural asymmetry
across the molecular two-fold axis that is consistent with these
CTP/UTP interactions. The synergistic inhibition of ATCase
by both CTP and UTP provides a satisfying logic for ensuring
a balance of endogenous pyrimidine nucleotide pools.
The aspartate transcarbamoylase (ATCase, EC 2.1.3.2) of
Escherichia coli provides a classic example of an enzyme
subject to allosteric control by the end product of its
biosynthetic pathway (1, 2). The holoenzyme of ATCase is
composed of two separable catalytic trimers (c3) and three
regulatory dimers (r2) that interact through a variety of
specific protein-protein interfaces (3, 4). These interactions
provide for specific conformational transitions (4-7) of the
holoenzyme, 2(c3):3(r2), which result in changes in the
catalytic rates and ligand affinities (8-10). Upon binding of
substrates and/or substrate analogues the enzyme appears to
make a concerted transition from an inactive "T conforma-
tion" (condensed form of the enzyme) to an expanded, more
active "R conformation" (5-7). CTP affects catalysis by
increasing the concentration of aspartate required to produce
maximal activity. In contrast, ATP decreases the substrate
requirement without altering the Vmax of the enzyme (1, 2).
Both nucleotide effectors have been shown to competitively
bind at the same allosteric sites even though they induce
different heterotropic effects on catalysis (11-14). Other
pyrimidine nucleotides, specifically UTP and TTP, do not
have any effect. GTP does promote a significant inhibitory
effect under some conditions (25-30%) but less than that of
CTP (50-70%). 8-Bromoguanosine 5'-triphosphate, as well as
gadolinium complexes of ATP, CTP, and GTP, binds to the
regulatory subunits, whereas UTP does not appear to bind to
the native enzyme (11-13). These allosteric controls have
been promoted for their inherent logic in balancing endoge-
nous purine and pyrimidine nucleotide pools; however, there
has always been a quantitative paradox relative to the
incomplete inhibition by CTP (10, 14, 15). In addition, it
appears that there is discrete heterogeneity in CTP binding as
half of the allosteric sites are capable of providing for
high-affinity binding of CTP whereas three additional, low-
affinity sites have been identified in some studies (16-19).
A potential structural basis for this "half-site reactivity"
has been provided by recent studies of Lipscomb and
coworkers (20) in which a molecular asymmetry has been
observed across the "two-fold axis of symmetry" of the
CTP-liganded enzyme. In the presence of saturating concen-
trations of CTP, one of the allosteric sites of each dimer is
fully occupied, whereas the second has an occupancy factor
of <0.4. This asymmetry is translated into differences in the
positioning of Arg-54 in the active sites and changes in the
interface of the regulatory and catalytic subunits. Thus when
the three CTP-binding sites on one side of the two-fold axis
of symmetry are filled, the catalytic sites in that half assume
a different conformation than the catalytic sites in the other
half of the holoenzyme. Similarly, the partially filled allo-
steric binding sites on the opposing half of the enzyme adopt
a different conformation than the completely filled CTP-
binding sites. Even though both opposing sets of active sites
and allosteric sites experience structural changes relative to
the unliganded holoenzyme, the nature of those rearrange-
ments is not identical. These differences appear to be divided
between the opposing catalytic subunits of the oligomer such
that the sites in each subunit are similar to one another but
distinct from those in the other subunit. In the same manner,
the allosteric sites in one half of the enzyme are occupied by
CTP, whereas those in the other half are only partially
occupied yet different from those observed in the unliganled
enzyme.
The observations presented in these studies identify a role
for UTP in completing the allosteric inhibition of ATCase by
pyrimidine nucleotides and permit the development of a more
complete model for metabolic regulation of pyrimidine bio-
synthesis.
MATERIALS AND METHODS
Enzyme Purification and Assay. The ATCase of E. coli was
overproduced from the plasmid KUR1278 (derived from
Abbreviations: ATCase, aspartate transcarbamoylase; SO.5, concen-
tration of substrate required for half-maximal activity; CPSase,
carbamoylphosphate synthetase.
*To whom reprint requests should be addressed.
46
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 86 (1989) 47
pPBhlO5 by transferring the Pst I-Sal I fragment into pUC8;
ref. 21) and expressed in E. coli EK1104 (22). To obtain
homogeneous holoenzyme preparations it was necessary to
utilize the heat step (720C) and a single pI precipitation (pH
5.9) of the purification procedures described by Gerhart and
Holoubek (23). The architectural purity of the enzyme was
verified by nondenaturing activity gel analysis and/or chro-
matography on DEAE-Sephadex (24). Enzymatic activity
was determined as described (25, 26) in the presence of
saturating carbamoyl phosphate (4.8 mM) and varying con-
centrations of aspartate depending upon the experimental
purpose. The assays were all performed at pH 7.0, 280C with
nucleotide effector concentrations varying from 0 to 12 mM.
Equilibrium Dialysis. The equilibrium binding of nucleotide
triphosphates was determined according to the general pro-
cedures of Tauc et al. (15) as modified to match the assay
conditions used to analyze the synergism of CTP and UTP
utilized in these studies (25). Nucleotide concentrations were
adjusted from 1 to 500 1LM, and the specific radioactivities of
the 3H-labeled NTPs (ICN-Biochemicals) were adjusted to
obtain -1000 cpm per 1l. The linearity of the equilibrium
binding was evaluated over concentrations of ATCase from
0.03 to 30.0 mg/ml, and 3.0 mg/ml (10 1LM) was utilized for
studies with [14CJCTP binding and 30 mg/ml was used for
UTP binding studies. Equilibrium was ensured by evaluation
after 36 and 72 hr at 40C. The purities of the radioactively
labeled nucleotides were determined by HPLC analysis as
described (27).
EXPERIMENTAL RESULTS
Relative Activities for Combinations of Nucleotide Effectors.
Table 1 summarizes the relative activities for various purine
and pyrimidine nucleotide effectors independently and in
combination. Saturating concentrations for each nucleotide
(2 mM) were used throughout the studies and nucleotide
effects were determined at the concentration of substrate
required for half-maximal activity (So.5) of the unliganded
enzyme (5 mM aspartate) and one-half that value (2.5 mM
aspartate). In each study, the effect of the nucleotides was
amplified at the lower substrate concentration. When satu-
rating concentrations of nucleotides were mixed, as previ-
ously reported (27), CTP reversed the activation by ATP.
Other nucleotides had very little effect on the ATP-induced
Table 1. Relative specific activities for combinations of
nucleotide effectors
Aspartatet
Nucleotide effector*
ATP
CTP
GTP
UTP
ATP/CTP
ATP/GTP
ATP/UTP
CTP/GTP
CTP/UTP
GTP/UTP
A/C/G*
A/C/US
A/G/Ut
C/G/Uf
A/C/G/Ut
2.5 mM 5.0 mM
1.86
0.31
0.57
0.95
0.70
1.98
1.96
0.41
0.05
0.66
1.78
0.07
1.95
0.05
0.63
1.35
0.43
0.71
0.95
0.85
1.58
1.52
0.58
0.06
0.84
1.60
0.11
1.70
0.11
0.92
activation ofATCase; neither UTP nor GTP counteracted the
ATP effect but actually promoted slight increases in activity.
The most interesting effects were observed from the combi-
nation of CTP and UTP, which resulted in a 90-95%
inhibition of ATCase at both aspartate concentrations. This
cooperative effect of CTP and UTP was maintained in the
presence of either ATP or GTP. It should be noted that CTP
was capable ofmaintaining inhibition in the presence ofeither
purine nucleotide alone. When all four nucleotides were
present simultaneously, slight inhibition (10-40%) was ob-
served. These results were most important because they
revealed a synergism between CTP and UTP in which UTP
could contribute to the allosteric inhibition of ATCase even
though it had no independent effect. In the presence ofATP,
GTP contributed to the activation of the enzyme, in spite of
its independent inhibitory effect, and provided a synergistic
companion for ATP to compete with CTP and CTP/UTP
combinations.
Synergistic Inhibition of CTP and UTP. To evaluate
whether the effect of combinations of CTP and UTP was a
nucleotide-specific synergism or a concentration-dependent
phenomenon, various overlapping effector response curves
were analyzed. The results presented in Fig. 1 demonstrate
that the UTP/CTP synergism was dependent upon both CTP
and UTP and could not be mimicked by high concentrations
of either nucleotide alone. Individual nucleotides demon-
strated first-order saturation kinetics relative to their allo-
steric effects. When the CTP concentration was maintained
at 2 mM and increasing concentrations of UTP were added,
catalytic activity was reduced to 5-10% ofthe control values.
Thus, it is clear that combinations of both CTP and UTP were
required to effect maximal inhibition of the native ATCase
from E. coli at pH 7.0. This effect is not as pronounced at pH
8.3 when UTP does have some independent inhibitory effect
(-15-20%) (data not shown).
Saturation Kinetics of Nucleotide Effectors. Fig. 2 demon-
strates that ATP appears to have a lower apparent binding
affinity than CTP based on kinetic saturation responses,
whereas UTP had no inhibitory effect at concentrations up to
12 mM. The half-saturating concentration for ATP activation
was 0.8 mM, whereas CTP-induced inhibition required levels
that were decreased by a factor of -5 (0.15 mM). This weaker
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FIG. 1. Synergistic inhibition of CTP and UTP. The saturation
kinetics of the effects of CTP and UTP on the activity of ATCase
were determined under standard assay conditions employing satu-
rating carbamoyl phosphate concentrations and 5 mM aspartate (pH
7.0). Percentage relative activity was measured at increasing con-
centrations of nucleotide (NTP). Independent effects of UTP (o) and
CTP (o) are depicted up to 4 mM. The synergistic effect of CTP and
UTP was determined by adding increasing concentrations of UTP to
saturating (2 mM) concentrations of CTP (v).
*Effector concentrations are 2 mM for each nucleotide.
tRelative activities represent specific activities with effector divided
by specific activity of ATCase without nucleotide ligands at the
indicated aspartate concentrations.
tA = ATP; C = CTP; G = GTP; U = UTP.
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FIG. 2. Comparative saturation kinetics ofATCase by nucleotide
effectors. The saturation kinetics for ATP, CTP, and UTP were
determined as described in the legend to Fig. 1.
binding of ATP has been described by others (19, 20) and
would explain the dominance of CTP inhibition over ATP
activation. The nature of this competitive advantage for CTP
can be described in a slightly different manner by evaluating
competitive saturation curves (data not shown). In these
studies, increasing concentrations ofeither CTP or ATP were
used to counteract saturating (2 mM) concentrations of the
other allosteric effector. The concentrations of nucleotide
required to overcome the effect of its antagonistic nucleotide
(to adjust the relative activity of the reaction to that of the
unaffected enzyme) were 0.8 mM CTP and =3.6 mM ATP.
These results are consistent with the competition ofATP and
CTP for the same binding sites with higher CTP-binding
affinities.
Synergistic Interaction of CTP and UTP in Effecting Ailo-
steric Inhibition. Saturation studies with combinations of
CTP and UTP were performed to evaluate the nature of the
synergistic interaction between the two nucleotides (Fig. 3).
In the presence of saturating concentrations of either CTP or
UTP (2 mM), the kinetic development of synergistic inhibi-
tion was more rapid than the partial inhibition induced by
CTP alone. The requirement for maximal CTP inhibition was
lower by a factor of -10 in the presence of UTP. Although
the concentration ofCTP required for half-maximal inhibition
was w0.15 mM at subsaturating concentrations of aspartate,
the requirement in the presence of UTP was <0.02 mM. In
fact, 0.02 mM concentrations of either UTP or CTP were
adequate to effect 50o inhibition in the presence of 2 mM
concentrations of the other nucleotide. Therefore, it appears
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FIG. 3. Enhancement of heterotropic inhibition of CTP by UTP.
Two millimolar concentrations of UTP were present while the effect
of increasing concentrations of CTP (o) on the relative specific
activity of ATCase was determined. Similarly, saturating concen-
trations ofCTP (2 mM) were augmented by increasing concentrations
ofUT-P (m) or saturating concentrations ofUTP were augmented with
increasing concentrations of CTP (A).
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FIG. 4. Aspartate saturation kinetics in the presence of nucleo-
tides. The aspartate saturation of ATCase activity was determined in
the presence of 2 mM concentrations of ATP (o), CTP (n), and CTP
+ UTP (m) as compared to the saturation kinetics in the absence of
nucleotide (e). Standard assay conditions were used except for
varying aspartate concentrations.
that the CTP/UTP synergism served to improve the inhibi-
tory effects of CTP as well as enhancing overall heterotropic
inhibition.
Aspartate Saturation in the Presence of Nucleotide Effectors.
Fig. 4 presents the kinetics of aspartate saturation in the
presence of ATP, CTP, and CTP + UTP. The SO.5 concen-
tration of aspartate in the absence of allosteric effectors was
-5.0 mM, whereas ATP reduced the value to 3.0 mM and
CTP elevated the concentration to 11.0 mM while the values
for Vm,,ax did not change. UTP had no independent effect on
either SO.5 or maximal activity. Millimolar concentrations of
both CTP and UTP demanded higher concentrations of
aspartate for activity and the So.s was -17.0 mM. Although
the effects of other nucleotides could be completely over-
come by higher aspartate concentrations, the CTP/UTP
affected enzyme did not appear to be able to regain the Vm,,,
of the unliganded enzyme (only 85% at 50 mM aspartate).
The kinetic parameters determined in the presence of various
nucleotide effectors are summarized in Table 2.
Equilibrium Binding of Nucleotide Triphosphates. Satura-
tion equilibrium binding studies demonstrated that 10 Amol of
protein binds -30 Amol of CTP (three sites per holoenzyme)
in the presence or absence ofUTP at pH 7.0. A Scatchard plot
of the data (Fig. 5) indicated that n = 2.8-3.0 in both cases.
Addition of varying concentrations of UTP (20-300 AM) or
phosphonacetyl-L-aspartate (100 ,M) did not affect the
number of tight binding sites for CTP. The binding constants
in the presence of phosphonacetyl-L-aspartate were esti-
mated from the data in Fig. 5 and it appears that UTP
enhances CTP binding 30-40% (Ks: CTP alone = 3 x 105
M-1; with 2 mM UTP = 4.3 x 105 M-1). Independent binding
Table 2. Kinetic parameters of ATCase in the presence of
nucleotide effectors
Nucleotide* Vmaxt So.st napp§ Effects
None 7.2 5.5 2.1 100
ATP 7.4 3.0 1.7 140
CTP 7.1 11.0 2.8 60
UTP 7.2 5.5 2.1 95
CTP/UTP 6.3 17.0 3.0 5
*Nucleotide concentrations were 2 mM for each effector.
tMaximal velocity estimated at saturating concentrations of sub-
strates (maximal velocity reported as ;Lmol/hr per tLg of protein).
tConcentration of aspartate required to produce half-maximal ve-
locity.
§Hill coefficient (±5%) estimated from aspartate saturation kinetics
(determined by slope of log V/[Vmax - v] vs. log S) (26).
Percentage relative activity at 5 mM aspartate.
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FIG. 5. Scatchard representation of CTP equilibrium dialysis
binding to native ATCase holoenzyme in the presence (A) and
absence (o) of 2 mM UTP. [Et], total enzyme concentration.
studies with UTP demonstrated that 4-12% of the total label
was associated with protein dependent on the concentration
ofUTP, but it was not possible to complete a saturation study
due to the insensitivity of the binding at higher concentra-
tions. In this sense, UTP demonstrated the weak binding
characteristic ofATP association rather than the tight binding
of CTP. The presence of 2 mM CTP did not detectably
enhance the binding ofUTP to the ATCase holoenzyme (data
not shown).
DISCUSSION
The ATCase of E. coli provides one of the classic models for
allosteric regulation of catalytic activity in which the end
product of a biosynthetic pathway controls the first unique
enzyme of the pathway. Several detailed reviews have been
published in recent years and describe an elegant enzyme
subject to homotropic and heterotropic ligand responses (8-
10). As the endogenous CTP pools increase, the heterotropic
inhibition of ATCase would directly modulate the de novo
synthesis of pyrimidine nucleotides. Furthermore, pyrimi-
dine nucleotide pools could be coordinated with purine
nucleotide pools through the competition ofATP and CTP for
the regulatory control ofATCase (11, 12, 14, 27), resulting in
an activation or inhibition of de novo pyrimidine biosynthe-
sis. From a metabolic perspective, it would seem that the
intracellular chemistry of the bacterial cell is poised to
maximize these allosteric interactions since the endogenous
metabolic pool for aspartate approximates the S0.5 ofATCase
(5 mM) and the nucleotide pools are =0.5-1.0 mM for CTP
and -2-3 mM for ATP (27) under conditions of steady-state
growth in E. coli. These physiological conditions would
provide the most sensitive responses for the allosterically
regulated enzyme since endogenous ligand concentrations
approximate the half-saturating values required for inducing
homotropic and heterotropic effects in vitro.
Despite this textbook characterization of ATCase, there
are a series of subtle incongruities that have been reported
relative to the enzyme from E. coli:
(i) CTP only inhibits the enzyme 50-70o under various
physical conditions, such as altered pH, substrate concen-
trations, or effector concentrations (1, 2, 10, 14, 27).
(ii) CTP appears to have only three tight binding sites
although it could be expected that there should be one
equivalent binding site for each of the six regulatory poly-
peptides. This half-site reactivity has been described by
several authors (16-19).
(iii) Recent structural refinement of the CTPATCase has
suggested that there is an asymmetry across the molecular,
two-fold axis of symmetry such that the active sites and r-c
interfaces of opposing halves of the enzyme are configured
differently. The mechanistic significance of the asymmetry
has not been determined (20).
The studies presented in this research provide a unifying
hypothesis for all of these observations. Thus it can be
postulated that CTP binding to half of the regulatory sites of
ATCase effectively restricts the catalytic efficiency of one of
the catalytic trimers, whereas the three sites of the other
subunit retain catalytic competency. Upon the tight binding
of CTP to the first set of allosteric sites, a structural
reorientation of the remaining binding sites could become
permissive for UTP or CTP binding, thus completing the
inactivation of ATCase. The binding of UTP did not appear
to facilitate the equivalent occupancy of all six allosteric sites
by CTP since there were only three tight binding sites for CTP
in the presence or absence of UTP. Nonetheless, the binding
of CTP was affected by the presence of UTP in that the K,
appeared to increase -20-30o (from 3 x 105 to 4 X 105 M-1).
CTP did not appear to affect the binding of UTP at pH 7.0
in either the presence or absence of phosphonacetyl-L-
aspartate. On the other hand, kinetic studies with combina-
tions of nucleotides indicate that CTP and UTP do possess a
direct, nucleotide-specific synergism that can be counter-
acted by high concentrations ofATP (>8 mM). Therefore, it
appears that the inhibitory synergism of CTP and UTP is the
result of enhanced CTP interactions at three regulatory sites
accompanied by some additional, permissive inhibition by
UTP. Detailed studies ofthe synergistic effects and structural
consequences of UTP and CTP binding are necessary.
This model is quite compelling for its inherent metabolic
logic, which would lead to an endogenous balancing of the
pyrimidine nucleotide pools (Fig. 6). Elevated levels of
intracellular pools of CTP alone would exert two simulta-
neous regulatory functions, as a partial inhibitor for the entire
de novo pathway through ATCase (1, 2) and for direct control
over its own synthesis through competitive inhibition ofCTP
synthetase (28). Since CTP alone only partially inhibits
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FIG. 6. Allosteric control patterns for de novo pyrimidine and
arginine biosynthesis in E. coli. CTP and UTP provide synergistic
feedback inhibition of ATCase, whereas ATP provides competitive
heterotropic activation. The feedback; inhibition of carbamoylphos-
phate synthetase (CPSase) by UMP is subject to antagonism by
ornithine (ORN) and the enzyme is activated by IMP. N-
Acetylglutamate synthase is subject to feedback inhibition by L-
arginine (ARG). The biosynthetic intermediates of the de novo
pyrimidine pathway are glutamine (GLN), carbamoylphosphate
(CP), aspartate (ASP), carbamoyl aspartate (CAA), dihydroorotic
acid (DHOA), orotic acid (OA), orotidine-5'-monophosphate (OMP),
and the common uridylates (UMP, UDP, and UTP). The identified
intermediates of the arginine biosyntheticpathway are glutamate(GLU), N-acetylglutamate (NAG), ornithine (ORN), citrulline
(CIT), arginosuccinate (ARGS), and arginine (ARG).
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ATCase, significant pyrimidine synthesis would continue;
however, this would primarily serve to increase the UTP pool
since the conversion of UTP to CTP would be restricted at
CTP synthetase. Ultimately, CTP and UTP pools would be
elevated, thus permitting the thorough inhibition of ATCase.
Concomitant with the increasing triphosphate pools, an ex-
panding UMP pool would provide for the inhibition of CPSase
and reduce the production of carbamoylphosphate for pyrim-
idine and arginine biosyntheses (29, 30). To ensure that
elevated pyrimidine nucleotide pools do not result in the
depletion of carbamoyl phosphate for arginine biosynthesis,
ornithine specifically antagonizes the UMP inhibition of CPS-
ase and is capable of independent activation (30). When
adequate levels of arginine are available, the ornithine pool
decreases as the result of feedback of the first enzyme of the
de novo pathway, N-acetylglutamate synthase (31). In addi-
tion to the heterotropic controls emanating from the de novo
pathways, various purine nucleotides (particularly, IMP and
ATP) provide for the allosteric activation of CPSase and
ATCase (1, 2, 29, 30). Thus elevated purine nucleotide pools
would stimulate the de novo synthesis of pyrimidine nucleo-
tides. The combination ofCTP and UTP provides a synergistic
control that effects the inhibition ofATCase in the presence of
purine nucleotides, and IMP is capable of competitive activa-
tion of CPSase relative to UMP. In this manner, CPSase and
ATCase are able to preside over the balancing of pyrimidine
nucleotide pools with their purine counterparts in E. coli.
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